[ad_1]
The media coverage of Dicerna Pharmaceuticals (NASDAQ: DRNA) has been rather positive recently, reports Accern Sentiment Analysis. Accern ranks corporate coverage on a scale from negative to positive, with scores closest to one being the most favorable. At the Accern scale, Accern also made the headlines of the biopharmaceutical company with an impact score of 46.8785069635998 out of 100, which means that recent media coverage is unlikely to occur. Affect the short-term share price.
Media articles that may have influenced Accern Sentiment rankings:
A number of research badysts have published reports on DRNA's actions. Ngine put Dicerna Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, April 12. Evercore ISI has re-evaluated its "outperformance" rating and issued a price target of $ 17.00 (previously $ 14.00) on Dicerna Pharmaceuticals shares in a report on Friday, April 20th. Cowen reinstated a "buy" note on Dicerna Pharmaceuticals shares in a report on Tuesday, April 24. BidaskClub has updated Dicerna Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, May 4th. Finally, HC Wainwright rebadessed its rating and issued a price target of $ 14.00 on Dicerna Pharmaceuticals shares in a report on Tuesday, May 15th. An investment badyst rated the stock with a sales rating, four issued a blocking note and five gave a buy note to the company. The company currently has an average "Hold" rating and an average target price of $ 12.88.
Dicerna Pharmaceuticals shares opened at $ 12.89 on Friday, according to MarketBeat Ratings reports. The company has a market capitalization of $ 685.63 million, a capitalization ratio of -3.52 and a beta of 2.35. Dicerna Pharmaceuticals has a low of fifty-two weeks of $ 2.69 and a high of fifty-two weeks of $ 15.80.
Dicerna Pharmaceuticals (NASDAQ: DRNA) last announced its quarterly results on Monday, May 14. The biopharmaceutical company reported earnings per share of $ 0.30 for the quarter, exceeding consensus estimates by Thomson Reuters by $ 0.57 ($ 0.87). Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1 665.11%. The activity generated a turnover of $ 1.55 million during the quarter, against $ 1.75 million for badysts. Analysts expect Dicerna Pharmaceuticals to post -1.35 EPS for the current year.
In addition, insider James B. Weissman sold 10,000 shares of the company on Wednesday, May 9. The stock was sold at an average price of $ 15.00, for a total transaction of $ 150,000.00. Following the conclusion of the sale, the insider now directly owns 19,800 shares of the company, valued at $ 297,000. The sale was disclosed in a document filed with the SEC, which is available on the SEC's website. Company insiders own 19.85% of the shares of the company.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare viral, hepatic and cardiovascular infectious diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic infection with the hepatitis B virus; and DCR-PCSK9 to treat hypercholesterolemia
Main article: Leveraged Buyout (LBO) Explained
Receive news & ratings for Dicerna Daily Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's free daily newsletter.
Source link
